Latvian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Berries, Inflammation, and Gut Microbiome

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
Saite tiek saglabāta starpliktuvē
StatussPieņemšana darbā
Sponsori
Clinical Nutrition Research Center, Illinois Institute of Technology
Līdzstrādnieki
USDA Beltsville Human Nutrition Research Center

Atslēgvārdi

Abstrakts

The primary objectives are to characterize changes in indices of systemic and gut inflammation, assess host- and microbial-derived metabolite pools, and describe and link functional metagenomics and metatranscriptomic alterations in the gut microbiome with metabolite and inflammatory outcomes after acute (24hr) and chronic (4 week) intake of anthocyanins and ellagitannins from strawberry and red raspberries compared to a control diet (negative control), FOS (positive control, non-polyphenol, carbohydrate-based fermentable fiber/pre-biotic), or combination diet (berry composite + FOS) in human participants with low-grade inflammation.

Apraksts

The proposed study will be conducted in humans according to Good Clinical Practice (GCP) guidelines. All subjects will review and sign an Informed Consent Form approved by the Illinois Institute of Technology's Institutional Review Boards (IRB) prior to screening.

This is a single-center, randomized, single-blinded, 4-arm, placebo-controlled clinical trial. It features an acute single exposure 24-h protocol and a chronic 4-week daily intake protocol to evaluate the effects of anthocyanins and ellagitannins from strawberry and red raspberry intake compared to a control diet, FOS, or FOS and berries combined on gut inflammation, in adults with chronic low-grade inflammation.

A planned sample size of 88 will be enrolled in the study. This study will require one initial screening visit, a pre-study visit, and 5 study visits. This study will take 5 weeks per subject to complete.

The initial screening visit will provide subject with their site-specific, IRB-approved informed consent document prior to the start of any study-related procedures. Subject eligibility will be determined through a high sensitivity C-Reactive Protein (hs-CRP) marker value, anthropometric measurements, vital signs, fasting blood glucose test (finger prick), and completion of a survey related to general eating, health, mood and exercise habits.

Eligible subjects will follow a limited polyphenolic diet throughout the duration of their participation, although stricter guidelines will be imposed during the 3 days prior to a study visit that involved blood/urine/fecal collection. Shopping lists and meal plans will be provided to subjects, along with counseling by the investigator's study investigators, to help subjects adhere to the limited polyphenolic diet. The trial will initiate with a 3-day food diary to assess background (pre-study) dietary intake followed by counseling to follow a diet relatively low in (poly)phenolic rich-beverages/foods, which will be maintained for the duration of the experiment. After an initial 7-day wash-in period on the limited polyphenolic diet, subjects will be randomized to 1 of 4 treatment sequences in the form of a drink: a mixed berries diet (raspberries and strawberries), a FOS diet (non-polyphenol, carbohydrate-based fermentable fiber/pre-biotic), a combination diet (mixed berries + FOS), or a control diet (negative control). Subjects will receive the same treatment for the duration of the study. Treatment codes will be maintained by the principal investigator.

Each visit will last ~2 hours and subjects will be required to remain at the Clinical Nutrition Research Center for the duration of the visit. Fasting blood samples will be collected at the 0 and 24h time points via a butterfly needle placed by a certified phlebotomist.

Datumi

Pēdējoreiz pārbaudīts: 01/31/2020
Pirmais iesniegtais: 09/17/2019
Paredzētā reģistrācija iesniegta: 09/18/2019
Pirmais izlikts: 09/23/2019
Pēdējais atjauninājums iesniegts: 02/09/2020
Pēdējā atjaunināšana ievietota: 02/11/2020
Faktiskais studiju sākuma datums: 10/06/2019
Paredzamais primārās pabeigšanas datums: 09/30/2021
Paredzamais pētījuma pabeigšanas datums: 08/31/2022

Stāvoklis vai slimība

Overweight or Obesity
Healthy

Iejaukšanās / ārstēšana

Dietary Supplement: Mixed Berries

Dietary Supplement: FOS

Dietary Supplement: Control

Dietary Supplement: Combination

Fāze

-

Roku grupas

RokaIejaukšanās / ārstēšana
Active Comparator: Mixed Berries
Strawberry and red raspberry composite served as a frozen drink
Dietary Supplement: Mixed Berries
Strawberry and red raspberry
Active Comparator: FOS
Non-polyphenol, carbohydrate-based fermentable fiber/pre-biotic served as a frozen drink
Dietary Supplement: FOS
Fructo-oligosaccharide
Active Comparator: Combination
Mixed berry composite + FOS served as a frozen drink
Dietary Supplement: Combination
Mixed berry composite + FOS
Placebo Comparator: Control
Placebo similar in color to mixed berry supplement without any polyphenols served as a frozen drink
Dietary Supplement: Control
Placebo similar in color to mixed berry supplement without any polyphenols

Atbilstības kritēriji

Vecums, kas piemērots studijām 20 Years Uz 20 Years
Dzimumi, kas ir piemēroti studijāmAll
Pieņem veselīgus brīvprātīgos
Kritēriji

Inclusion Criteria

- C-Reactive Protein (hs-CRP) > 1.0 and ≤ 10 ng/L

- BMI ≥ 25 kg/m2

- Aged 20-60 years

- Able to provide informed consent and comply with study procedures

- Willing to maintain stable body weight and follow his/her habitual diet and physical activity patterns throughout the trial.

- Judged by the Investigator to be in general good health on the basis of medical history and screening laboratory tests.

- People with no documented disease condition that would interfere with the study endpoints (ie., CVD, diabetes, hypertension, major organ diseases) or taking medication or dietary supplements that may interfere with study endpoints

Exclusion Criteria

- Current smoker or marijuana user

- No history or presence of atherosclerosis/cardiovascular disease, inflammatory disease, diabetes mellitus, or other systemic diseases, psychological or psychiatric disorders that may interfere with study outcomes.

- Taking any medications and/or supplements that would interfere with outcomes of the study (i.e., lipid-lowering medications, anti-inflammatory drugs, etc)

- Take part in prebiotics, probiotics or drugs active on gastrointestinal motility or a laxative of any class within 1 month

- Unstable use of any medication/supplement, this could include marijuana used as -needed for medical reasons

- Have a history of cancer, except for non-melanoma skin cancer in past 5 years

- Addicted to drugs and/or alcohol (>4 drinks/day)

- Have been exposed to any non-registered drug product within last 30 days.

- Working overnight (e.g. 3rd shift of overnight workers)

- Excessive exercisers or trained athletes

- Have allergies/intolerances to any of the study products.

- Extreme dietary habits (ie. vegetarian/vegan)

- Excessive coffee/tea drinker (>4 cups/day)

- Actively losing weight/ trying to lose weight (unstable body weight fluctuations of > 5 kg in 3 months)

- Donated blood within last 3 months

- Participated in a clinical trial within 1 month

- Female who is pregnant, planning to be pregnant, breastfeeding

- Any condition the Investigator believes would interfere with his or her ability to provide informed consent or comply with the study protocol, or which might confound

Rezultāts

Primārie rezultāti

1. Changes in plasma biomarkers and measures of inflammation concentration: Nrf2/ NF-κB -response between 4 treatments [Baseline to 4 weeks]

Plasma biomarkers and measures of inflammation: Nrf2/ NF-κB activation in monocytes will be analyzed.

2. Changes in plasma biomarkers and measures of inflammation concentration-response between 4 treatments [Baseline to 4 weeks]

Inflammatory cytokines (Interleukin-6 (IL-6), High Sensitivity C-Reactive Protein (hs-CRP), Tumor Necrosis Factor-α (TNF-α)) will be measured.

3. Changes in plasma biomarkers and measures of inflammation concentration (GLP-2)-response between 4 treatments [Baseline to 4 weeks]

Analysis of GLP-2 will be done in plasma samples before and after chronic exposure to the study foods.

Sekundārie iznākuma mērījumi

1. Changes in gut inflammatory markers between 4 treatments. [Baseline to 4 weeks]

The concentration of calprotectin, zonulin, and IgA in fecal samples will be determined by enzyme-linked immunosorbent assay (ELISA) before and after chronic exposure to study foods.

2. Changes in Bile acids between 4 treatments. [Baseline to 4 weeks]

Bile acids in plasma and fecal samples will be determined using UHPLC-QQQ-MS.

Citi iznākuma pasākumi

1. Characterize metabolite profiles (phenolic acids and urolithin derivatives) in urine and plasma. [Baseline to 4 weeks]

Polyphenolic metabolites (anthocyanin, ellagitannins and other phenolic components) will be identified and quantified in urine and plasma.Metabolites in samples will be identified and quantified using an Agilent 6550 iFunnel UHPLC-QTOF-MS and 6460 UHPLC-QQQ-MS, respectively.

Pievienojieties mūsu
facebook lapai

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne

  • Darbojas 55 valodās
  • Zāļu ārstniecības līdzekļi, kurus atbalsta zinātne
  • Garšaugu atpazīšana pēc attēla
  • Interaktīva GPS karte - atzīmējiet garšaugus atrašanās vietā (drīzumā)
  • Lasiet zinātniskās publikācijas, kas saistītas ar jūsu meklēšanu
  • Meklēt ārstniecības augus pēc to iedarbības
  • Organizējiet savas intereses un sekojiet līdzi jaunumiem, klīniskajiem izmēģinājumiem un patentiem

Ierakstiet simptomu vai slimību un izlasiet par garšaugiem, kas varētu palīdzēt, ierakstiet zāli un redziet slimības un simptomus, pret kuriem tā tiek lietota.
* Visa informācija ir balstīta uz publicētiem zinātniskiem pētījumiem

Google Play badgeApp Store badge